Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

The proceedings reached its superior goal, with 40.6% of patients receiving mitapivat demonstrating a 1.0 g/dL oregon higher summation successful hemoglobin levels, successful examination to 2.9% successful the placebo group. The medication, however, did not importantly little the annualized complaint of sickle compartment symptom episodes.

That said, Leerink Partners sees the approaching thalassemia PDUFA day of December 7 arsenic a near-term catalyst that is not reflected successful existent banal prices. The steadfast pointed retired that this way mightiness entail a commercialization concern successful important markets and imaginable support for a wider assemblage compared to rival luspatercept.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is simply a commercial-stage biopharmaceutical institution focused connected therapies for uncommon diseases, peculiarly successful cellular metabolism. Its flagship product, PYRUKYND (mitapivat), targets hemolytic anemias, including sickle compartment illness and thalassemia.

While we admit the imaginable of AGIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.